Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
Date:1/15/2009

COLUMBUS, Ohio, Jan. 15 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of their Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250mg, 500mg, 750mg, 1000mg, and Oral Solution 100mg/mL. The product is available for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Levetiracetam Tablets and Oral Solution are AB rated to UCB, Inc.'s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) Tablets and Oral Solution are approximately $1.28 Billion (1).

Full prescribing information for Levetiracetam Tablets and Oral Solution is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

    (1) IMS MAT dollar sales ending 10/2008

    KEPPRA(R) is a registered trademark of UCB, Inc.

    Editorial Contact for Roxane Laboratories:
    Angela Chirico, 614.272.4774
    Angela.Chirico@boehringer-ingelheim.com


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
2. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
3. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
6. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
7. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
8. Charleston Laboratories, Inc. Phase I Clinical Trial
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
10. Ben Venue Laboratories, Inc. Named Recipient of the Governors Award for Outstanding Achievement in Environmental Stewardship
11. Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is a ... As a means of expanding capabilities Flottman has added a G&K Vijuk TTM ... professional inserts (PIs) and patient package inserts (PPIs) that will marry with all ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide ... Columbia as an education tool in the war against teen drug abuse. NCADD ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a device ... The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is also ... a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is a ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology: